Harnessing Data-Driven Insights and Innovations to Enhance AMD and DME Management: Strategic Approaches for Managed Care

This activity was originally broadcast in conjunction with AMCP 2025.

Program Description

Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are serious effects of diabetic retinopathy that patients can experience. The pathways for these disease states are based primarily around angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). These factors can cause inflammation, leakage, discomfort, and vision impairment for patients. The first-line treatment for nAMD and DME is monotherapy with an anti-VEGF agent. This treatment conveys a heavy burden on both patients and providers, with frequent scheduled injections and patient monitoring required. Pharmacists can contribute to the care management of patients with nAMD and DME by becoming familiar with emerging therapies that have a unique dual mechanism. These therapies have the potential to improve outcomes as well as reduce treatment burden for the patient. This panel discussion led by experts will inform managed care professionals about current treatment guidelines as well as present evidence for the role of emerging therapies in the improvement of outcomes for patients with nAMD and DME.

Target audience: Managed care pharmacists

Type of activity: Application
Release date: April 10, 2025
Expiration date: April 10, 2026

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the incidence, prevalence, and unmet needs of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), including economic impact and patient challenges.
• Analyze the efficacy, safety, and administration considerations of available and emerging therapies for nAMD and DME, emphasizing how these factors influence treatment selection and patient management.
• Apply managed care considerations that incorporate evidence-based guidelines and real-world evidence to improve treatment efficacy, balance cost-effectiveness, and enhance patient access to innovative therapies.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-089-H01-P. The activity is available for CE credit through April 10, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Rishi P. Singh, MD, has the following relevant financial relationships with commercial interests to disclose: Grant/Research Support: Janssen; Consultant: Alcon, Apellis Pharmaceuticals, Bausch + Lomb, EyePoint Pharmaceuticals, Genentech, Iveric Bio, Regeneron Pharmaceuticals, Regenxbio, and Zeiss.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Winston Wong, PharmD

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.

 
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms